PT-141 Peptide (Bremelanotide): How It Works, Uses, and Safety

PT-141, also called bremelanotide, is a synthetic peptide that activates melanocortin receptors in the brain to increase sexual desire and arousal [1]. The FDA approved it in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD) [2]. Clinicians also prescribe compounded bremelanotide off-label for men with low libido or erectile dysfunction that does not respond to Viagra or Cialis [3].

What is PT-141 (bremelanotide)?

PT-141 is the research name for bremelanotide (INN), a small synthetic peptide made of seven amino acids. It belongs to a drug class called melanocortin receptor agonists, meaning it binds to and activates melanocortin receptors — particularly the MC4 receptor — in the central nervous system [1].

Origin: from Melanotan II to a melanocortin agonist

Researchers originally developed PT-141 from Melanotan II, a peptide studied in the 1990s as a sunless tanning agent. During early trials, participants reported unexpected sexual arousal as a side effect. Scientists modified the molecule to remove the tanning activity and keep the sexual-response effect, which became bremelanotide [3].

FDA-approved brand: Vyleesi

Bremelanotide is sold under the brand name Vyleesi. The FDA approved it in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) — meaning low desire that causes distress and is not explained by another medical or relationship cause [2].

Compounded bremelanotide via 503A pharmacies

Outside the Vyleesi brand, bremelanotide is also available as a compounded medication prepared by licensed 503A compounding pharmacies under a clinician's prescription. This is common for patients who need a different dose form or for off-label uses such as low libido in men. Learn more about how this works in our overview of compounded peptides.

How does PT-141 actually work?

PT-141 works through the brain, not the bloodstream. That is what makes it different from every other prescription option for sexual dysfunction.

Melanocortin (MC4) receptor activation

Bremelanotide binds to melanocortin receptors — primarily MC4 — that sit on neurons in the hypothalamus, a region of the brain that regulates appetite, arousal, and many basic drives [1][4].

Dopamine release in the hypothalamus

Activating MC4 receptors triggers a downstream release of dopamine in the medial preoptic area of the hypothalamus. Dopamine is the brain's main "motivation and reward" signal, and in this circuit it is closely tied to sexual desire and arousal [4].

Why it works when Viagra and Cialis don't

Sildenafil (Viagra) and tadalafil (Cialis) are PDE5 inhibitors. They relax blood vessels in the penis so that an existing arousal signal can produce an erection [5]. If the desire signal itself is weak, more blood flow does not help. PT-141 targets the desire signal upstream, which is why it has been studied in men whose ED does not respond to PDE5 inhibitors [3].

What is PT-141 used for?

Hypoactive sexual desire disorder (HSDD) in women

The only FDA-approved use of bremelanotide is for premenopausal women with HSDD. In the RECONNECT phase 3 trials, women using bremelanotide reported statistically significant improvements in desire scores and reductions in distress compared with placebo, though the average size of the effect was modest [6].

Off-label use for men with low libido or ED

Early clinical studies in men with erectile dysfunction found that bremelanotide improved erectile response, including in men who had not responded well to sildenafil [3]. Larger phase 3 trials in men are still limited, which is why this use remains off-label.

Use alongside PDE5 inhibitors

Some clinicians have explored using low-dose bremelanotide together with a PDE5 inhibitor, on the theory that one drug addresses desire and the other addresses blood flow. Combination use can stack side effects — particularly on blood pressure — and should only be considered under medical supervision [3].

How long does PT-141 take to kick in?

Onset window for men

After a subcutaneous injection, bremelanotide typically begins to work within 30 to 60 minutes, with peak blood levels around one hour [2]. Most product labeling recommends dosing about 45 minutes before anticipated sexual activity.

How long effects last

The desire and arousal effects can last several hours, though the medication is cleared from the body over roughly 24 hours [2]. Individual results vary — onset and duration depend on body weight, metabolism, and other medications.

PT-141 dosing and how it is administered

Subcutaneous injection basics

Bremelanotide is given as a subcutaneous injection — a small needle into the fat layer of the abdomen or thigh. Vyleesi is sold as a pre-filled auto-injector; compounded bremelanotide is usually drawn from a vial with a small syringe [2].

Typical timing before activity

Educationally, the FDA label for Vyleesi describes dosing at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month [2]. Compounded protocols vary and are set by the prescribing clinician.

Why dosing should be set by a clinician

Dosing in clinical studies has ranged widely depending on the formulation and the population being studied. Because bremelanotide raises blood pressure transiently and interacts with other medications, dose selection should always be made by a licensed clinician who knows your medical history — not copied from an online forum.

PT-141 vs Viagra and Cialis: what's the difference?

PT-141 acts on the brain to drive desire; PDE5 inhibitors act on blood vessels to support an erection. They solve different problems.

When each option fits best

If the main issue is getting or keeping an erection when desire is already present, a PDE5 inhibitor is usually the first-line option [5]. If the main issue is low desire, or if PDE5 inhibitors have not helped, a clinician may consider bremelanotide.

What are the side effects and risks of PT-141?

Common side effects

• Nausea — the most common side effect, reported in roughly 40% of women in the Vyleesi trials, usually within the first hour after injection [2][6].
• Flushing of the face and chest.
• Headache.
• Injection-site reactions (redness, soreness).
• Vomiting and dizziness in a smaller share of users.

Blood pressure considerations

Bremelanotide can cause a transient rise in blood pressure (typically 6 mmHg systolic) and a small drop in heart rate within the first few hours after a dose [2]. This is why the FDA label says Vyleesi should not be used in people with uncontrolled hypertension or known cardiovascular disease [2].

Skin pigmentation changes

Because bremelanotide acts on melanocortin receptors, a small number of users develop focal darkening of the skin (hyperpigmentation) on the face, gums, or breasts, especially with repeated use. This is more likely in people with darker skin tones and may not fully reverse after stopping [2].

Who should not take PT-141

• People with uncontrolled high blood pressure or known cardiovascular disease [2].
• People who are pregnant or trying to become pregnant (bremelanotide is not approved in pregnancy) [2].
• Anyone taking certain oral medications that bremelanotide may slow the absorption of, including naltrexone [2].
• People with a known allergy to bremelanotide or any inactive ingredient.

Is PT-141 legal to buy?

Prescription-only status

In the United States, bremelanotide is a prescription-only medication. The only legal paths to get it are (1) a Vyleesi prescription filled at a standard pharmacy or (2) a prescription for compounded bremelanotide filled at a licensed 503A compounding pharmacy [2][7].

Research-only "gray market" vials

Compounded bremelanotide from licensed 503A pharmacies

503A pharmacies are state-licensed pharmacies that prepare customized medications for individual patients with a valid prescription. Compounded bremelanotide is regulated through this pathway and is currently part of the FDA's broader review of peptide compounding [7]. Read more in our explainer on longevity peptides and 503A compounding.

What peptides stack well with PT-141?

In clinical and research practice, PT-141 is sometimes discussed alongside other peptides that address related goals. There are no combination-specific FDA approvals, and these stacks should always be supervised by a clinician.

• BPC-157 — studied for tissue repair and circulation. Some clinicians combine it for general recovery, but the two have not been studied together in trials, and any cardiovascular side effects of bremelanotide still apply.
• CJC-1295 / Ipamorelin — a growth-hormone-axis pair sometimes used for body composition and sleep. Side effects do not heavily overlap with PT-141, but combined use means more injections, more variables, and more reason for clinician oversight.
• PDE5 inhibitors (sildenafil, tadalafil) — not peptides, but the most common pharmacologic pairing for sexual function. Combining drugs can compound effects on blood pressure, so screening is required.

How to get PT-141 through a licensed provider

What a telehealth evaluation looks like

A telehealth evaluation for bremelanotide typically includes a medical history review, a check on blood pressure and cardiovascular risk, a review of current medications, and a discussion of your goals. For women, the clinician will assess whether HSDD criteria are met; for men, the clinician will explain that use is off-label.

Eligibility and screening

Common reasons a clinician will not prescribe bremelanotide include uncontrolled high blood pressure, known cardiovascular disease, pregnancy, or interacting medications [2]. A recent blood pressure reading is usually requested before a first prescription.

Getting a prescription via Chia

Chia is one of several licensed telehealth providers that can evaluate patients for compounded bremelanotide. If you are a fit, a Chia clinician can issue a prescription that is dispensed by a partner 503A compounding pharmacy. You can also explore our broader telehealth peptide prescription overview to compare options.

Frequently asked questions

Keep reading

Peptides

Peptide Injections: What They Are, How They Work, and What to Expect

Peptides

Peptide therapy in 2026 (beyond GLP-1): an educated patient's guide

Peptides

Dihexa: the "million-fold BDNF" cognitive peptide — 2026 evidence-based guide